DNA methylation

Where the papers sit

12 papers from the last 6 months study DNA methylation directly · updated from PubMed 3 Oct 2026

• Epigenetic Health Risk

  Epigenetic markers are being tested as contributors to obesity, diabetes, blood pressure, cardiovascular risk, and skeletal development rather than treated as passive correlates. Mendelian randomisation probes causality in diabetes and early-life risk, while methylation editing of runx2 b examines inheritance of an acquired bone phenotype. PPAR signaling and transcription-factor regulation connect environmental exposure to downstream traits. Evidence remains trait- and age-specific, moving the field toward causal validation rather than a unified clinical intervention.

  5 papers · 41.7%

• Cancer Methylation Biomarkers

  DNA methylation is being developed as a cancer classifier and minimally invasive risk marker, with circulating cell-free DNA used to detect advanced breast cancer and classify estrogen receptor status. Pan-cancer models seek broad diagnostic performance, while tissue methylomes distinguish upper aerodigestive tract and sarcomatoid squamous carcinomas. In hepatocellular carcinoma, methylation-linked biomarkers such as PSMA1, PSMA5, and PSMB2 are tied to prognosis and tumor-infiltrating leukocytes. The recurring goal is clinically useful stratification, although cross-cancer generalization and biological interpretation remain open.

  4 papers · 33.3%

• Others — Methylation and Metabolic Biomarkers

  DNA methylation is being combined with metabolomics and molecular surveillance to connect epigenetic states with disease activity. In SLE, integrated signatures are associated with flare remission, while an epigenetic liquid biopsy tracks high-risk neuroblastoma without requiring a recurrent mutation. In metabolic dysfunction-associated fatty liver disease, DNMT-related control of the urea cycle is examined as a treatment mechanism, with bilirubin and metabolic measures among the readouts. The shared direction is biomarker-guided monitoring and mechanism, but the diseases and endpoints are too disparate to form one coherent programme.

  3 papers · 25%